Vinpocetine forte

General characteristics. Structure:

Active ingredient: 10 mg of a Vinpocetine in 1 tablet.

Excipients: potato starch, lactoses monohydrate, cellulose microcrystallic, magnesium stearate, talc, povidone.

Pharmacological properties:

Pharmacodynamics. The Vinpocetine is to synthetic derivatives of Vincaminum, possesses vasodilating action and influences a metabolism in a brain.

In pilot preclinical trials it is revealed that the mechanism of action of a Vinpocetine is connected with phosphodiesterase inhibition that promotes increase in the tsAMF level, increase in a blood-groove due to reduction of vascular resistance; reduction of aggregation of thrombocytes, improvement of microcirculation due to increase in deformability of erythrocytes; increase in utilization by glucose neurons; increase in tolerance of cells of a brain to a hypoxia and ischemia; increase in maintenance of neurotransmitters of a dopamine and noradrenaline, nootropic action contacts this effect.

Pharmacokinetics. After intake the Vinpocetine is soaked up in digestive tract. The maximum concentration is reached in 1,5 hours. Bioavailability of a Vinpocetine varies in the range of 7-57% and increases at a concomitant use with food. The volume of distribution makes about 3 l/kg at persons of young age and about 7 l/kg at elderly people.

The Vinpocetine is metabolized, mainly, in a liver, the main metabolite apovinkaminovy acid, apparently, is deprived of pharmacological activity. The Vinpocetine and a metabolite are removed, mainly, by kidneys. The elimination half-life depends on a dose of a Vinpocetine, the mode of dosing and makes 2-5 hours.

Indications to use:

Neurology: a symptomatic treatment of the cognitive disturbances connected with cerebrovascular diseases (the recovery period after an ischemic stroke, the tranzitorny ischemic attack, an effect of an ischemic stroke, distsirkulyatorny encephalopathy).

Before an initiation of treatment it is necessary to exclude the degenerative diseases of a nervous system which are not connected with vascular pathology (for example, Alzheimer's disease).

Ophthalmology: chronic vascular diseases of a choroid and retina of an eye.

Otology: decrease in hearing of perceptual character, Menyer's disease, a ring in ears.

Route of administration and doses:

For intake: on 5-10 mg 3 times a day within no more than 30 days, further on 5 mg 3 times a day within 2 months. Possible advantages of longer reception of medicine are not known.

Pill should be taken during food, without chewing.

To patients with diseases of kidneys appoint the above-stated doses.

To patients with a liver failure to appoint with care.

Features of use:

Pregnancy and lactation. The Vinpocetine is contraindicated to use at pregnancy. In need of its use in the period of a lactation it is necessary to stop breastfeeding.

Use in pediatrics. Safety and efficiency of use of a Vinpocetine for children is not established. Experience of use of a Vinpocetine for patients aged up to 18 years is limited. Use for children up to 18 years is not recommended due to the lack of adequate data.

Use for persons with an abnormal liver function and kidneys. Patients should not appoint medicine with liver diseases with the expressed dysfunction.

Use for persons with cardiovascular pathology. It is necessary to be careful at purpose of a Vinpocetine to the patients accepting the antihypertensives or medicines extending QT interval (лоратадин, терфенадин, erythromycin, probucol and others) or QT having a syndrome of prolongation of an interval in the anamnesis.

It is not recommended to appoint a Vinpocetine to patients with the labile arterial pressure and a low vascular tone.

To appoint with care to patients with the hypersensitivity, known from the anamnesis, to the drugs containing active ingredient similar to a Vinpocetine (alkaloids of the Periwinkle of small (Vinca minor)).

Due to the content of lactose medicine is not recommended to patients with rare inborn intolerance of a galactose, deficit of lactase of Lapp or malabsorption of glucose galactose.

Influence on ability to driving of motor transport and control of mechanisms. The patients accepting a Vinpocetine have to abstain from potentially dangerous types of activity connected with need of special attention and bystry psychomotor reactions.

Side effects:

Possible side reactions are listed below with the indication of frequency of occurrence (infrequently ≥ 1/1000 to <1/100, it is rare ≥ 1/10000 to <1/1000, it is very rare <1/10000).

Mental disorders. Seldom: sleep disorders, excitement, concern.

From a nervous system. Infrequently: headache; seldom: concern, paresthesias.

From an acoustic organ and vestibular mechanism. Infrequently: dizziness.

Heart pathology. Seldom: tachycardia, premature ventricular contraction, ST segment depression, lengthening of an interval of QT.

Vascular disorders. Infrequently: lowering of arterial pressure.

Gastrointestinal frustration. Seldom: abdominal pains, nausea; very seldom: gastrointestinal frustration, dyspepsia.

From skin and hypodermic cellulose. Infrequently: skin rash or itch.

Allergic reactions are possible.

Interaction with other medicines:

Interaction with anti-hypertensive, antiarrhytmic and anticoagulating medicines is possible. In case of need co-administration of a Vinpocetine with the specified medicines it is necessary to watch carefully a condition of the patient, control of arterial pressure, an ECG, indicators of system of a blood coagulation is recommended.

Contraindications:

– hypersensitivity to active ingredient or other components of medicine;

– heavy disturbances of a cordial rhythm;

– severe forms of coronary heart disease;

– the increased intracranial pressure;

– the postponed intracerebral bleeding;

– period of pregnancy and lactation.

Overdose:

Information on cases of overdose is absent. In case of overdose general measures on removal of medicine from an organism, the symptomatic treatment directed generally are recommended for maintenance of functions of heart and lungs.

Storage conditions:

In the place protected from light and moisture, at a temperature from 15 °C to 25 °C. To store in the place, unavailable to children. A period of validity - 2 years. Not to apply after the termination of a period of validity.

Issue conditions:

According to the recipe

Packaging:

On 10 tablets in a blister strip packaging; in packaging No. 10×3, No. 10×6.